Does estrone‑3‑glucuronide (E1G) dip during embryo implantation in a reproductive‑age woman?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 21, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

E1G Pattern During Embryo Implantation

Estrone-3-glucuronide (E1G) does not exhibit a characteristic "dip" during embryo implantation; instead, E1G levels continue to rise progressively after ovulation in conception cycles, reflecting ongoing corpus luteum activity and early placental hormone production.

Normal E1G Pattern in Conception Cycles

The physiologic pattern of E1G in cycles resulting in pregnancy follows a predictable trajectory:

  • E1G rises sharply during the late follicular phase, reaching a peak approximately 4-5 days before the LH surge (Day LH-4.7, range -3 to -6), which serves as the primary marker of impending ovulation 1

  • After ovulation, E1G levels remain elevated or continue to increase in conception cycles, sustained by corpus luteum function and subsequently augmented by trophoblastic hormone production 2, 3

  • No characteristic decline or "implantation dip" in E1G has been documented in the scientific literature examining urinary hormone patterns during early pregnancy 2, 4, 5

Distinguishing E1G from Progesterone Metabolites

A critical distinction must be made between estrogen and progesterone patterns:

  • Pregnanediol-3-glucuronide (PdG), not E1G, shows the dramatic post-ovulatory rise that confirms ovulation, with a 7-fold increase from follicular to luteal phase values 2

  • E1G provides information about follicular development and ovarian estrogen production, while PdG reflects corpus luteum function and progesterone secretion 3, 5

  • The ratio of E1G to PdG changes across the cycle, but neither hormone exhibits a consistent dip at the time of implantation (approximately 6-10 days post-ovulation) 2

Clinical Monitoring Implications

For women monitoring fertility or early pregnancy:

  • E1G peaks occur 3-6 days before the LH surge, making sustained rises in E1G useful for predicting the fertile window, but not for detecting implantation 1

  • Reliable E1G measurement requires correction for urinary creatinine concentration to reduce day-to-day variation from 40% to 25%, with morning urine specimens providing the most consistent results 2

  • Home monitoring of E1G using validated devices shows good correlation with laboratory radioimmunoassay (correlation coefficients >0.84 in 80% of cycles), though a systematic bias causes home monitor E1G values to read higher than RIA 4

Common Pitfalls to Avoid

Do not confuse the "implantation dip" phenomenon sometimes described for basal body temperature with E1G patterns—these are entirely different physiologic measurements, and the implantation dip concept lacks robust hormonal evidence 3

Avoid interpreting transient E1G fluctuations as clinically significant without considering the substantial day-to-day coefficient of variation (25-40%) inherent in urinary steroid measurements 2

Do not rely on E1G alone to confirm ovulation—PdG rise following an E1G peak provides the definitive evidence of ovulation, with specific PdG thresholds distinguishing anovulatory cycles (with or without luteinized unruptured follicles) from ovulatory fertile cycles 3

Related Questions

In a reproductive‑age woman tracking urinary estrone‑3‑glucuronide (E1G), does the level drop after embryo implantation or remain elevated/increase?
Does estrone (e1g) level increase 7-10 days post peak in the luteal phase in a female patient of reproductive age, and if so, how much does it rise above baseline levels?
Does a rising estrone-1-glucuronide (E1G) level, from 110.5 to 128.4, indicate early pregnancy in a female of reproductive age attempting to conceive?
For an adult woman being evaluated for ovulation or undergoing assisted reproductive treatment, is an overnight first‑morning urine sample required for accurate estrone‑3‑glucuronide (E1G) measurement, or is a six‑hour collection without voiding sufficient?
Is my estrone‑glucuronide (E1G) level of 43.8 µg on cycle day 20 (seven days after the LH surge) appropriate for early pregnancy while I am receiving progesterone supplementation?
What electrocardiographic abnormalities are seen in acute pulmonary edema?
Is it safe to administer morphine to a patient with multiple myeloma and impaired renal function (serum creatinine 2.2 mg/dL)?
What is the appropriate management for peripheral neuropathy?
In a fetus currently 36 weeks gestation with a neurosonogram at 40 weeks showing a mildly prominent left lateral ventricle (mild ventriculomegaly), when should follow‑up imaging be performed?
What is the recommended acute management for a patient with stress cardiomyopathy (Takotsubo syndrome)?
What diagnostic work‑up and first‑line treatment are recommended for a patient with focal seizures involving the right lower limb?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.